Longevity biotech spawns klotho-focused subsidiary

Klothea Bio launches to focus on developing therapeutics for age-related diseases based on klotho protein.

Longevity biotech ADvantage Therapeutics Inc. has announced the launch of Klothea Bio, a subsidiary company focused on advancing the research and development of therapies centered on the klotho protein. Klotho plays a pivotal role in maintaining health through mechanisms such as regulating phosphate homeostasis, suppressing oxidative stress and reducing inflammation associated with cellular aging. It also has protective effects on the cardiovascular system and brain function.

My take on this: Studies show that mice lacking klotho age faster and have shorter lifespans, while those with higher levels of klotho enjoy longer, healthier lives. However, klotho naturally decreases with age, a drop associated with conditions like cognitive decline, chronic kidney disease, high blood pressure, heart problems, and a higher risk of cancer.

“Klotho is a protein possessing multiple beneficial and unique pleotropic functions by protecting organs against inflammation, oxidative stress, tumor growth, while its absence leads to age-related diseases and early death,” said Advantage Therapeutics’ CSO, Dr Carmela Abraham , who has studied and worked on Klotho for more than 20 years.

To address the challenges posed by declining Klotho levels, Klothea Bio leveraging an mRNA-based approach that aims to enhance the body’s natural production of the protein to achieve sustained therapeutic effects. The company’s initial studies will target metabolic syndrome, a cluster of conditions including obesity, high blood pressure and high cholesterol, which are often precursors to more severe aging-related diseases. Following these studies, the scope of Klothea’s research is expected to expand to include conditions such as cancer, Alzheimer’s disease and other age-associated conditions.

“As we embark on this exciting journey, we expect to demonstrate that our mRNA therapy will increase significantly the levels of Klotho to those found in young and healthy individuals and will offer the potential for longer-lasting therapeutic effects which may delay or prevent certain age-related diseases,” said Jeffrey Madden , Chairman of Klothea Bio.

Learn more about Klothea Bio HERE.

Thanks for reading! If you’ve enjoyed this article, it would mean a lot to me if you could subscribe and share it on LinkedIn!